China News Service, Beijing, September 22 (Reporter Yu Zhanyi) September 22 is the International Slow Particle Day. On this occasion, Professor Jiang Qian, deputy director of the Department of Hematology, Peking University People’s Hospital, said that with the continuous development of modern medicine , Chronic granule has changed from an "incurable disease" to a treatable and controllable "chronic disease". At present, innovative drugs have been submitted for new drug marketing applications in China.

　　Chronic myelogenous leukemia (hereinafter referred to as "chronic myeloid") was once considered an "incurable disease", and was the first human tumor to be shown to be related to chromosomal abnormalities, due to the interaction between chromosomes 9 and 22 in the patient's body. Translocation, resulting in the formation of a new gene.

CML is a malignant tumor formed by clonal proliferation of bone marrow hematopoietic stem cells, which accounts for 15% of adult leukemias.

The global annual incidence rate is 1.6-2 per 100,000.

Chinese patients with CML are younger than those in the West. Epidemiological surveys in several regions in China have shown that the median age of onset of CML is 45-50 years old, while the median age of onset of CML in Western countries is 67 years.

　　It is understood that in 2001, the world's first tyrosine kinase inhibitor (TKI) appeared, marking that tumor therapy has entered the era of targeted therapy.

Over the past 20 years, the treatment pattern of slow particles has also undergone earth-shaking changes.

　　"With the continuous development of modern medicine, CML has changed from an'incurable disease' to a curable and controllable'chronic disease.' Drug dilemma." Jiang Qian pointed out that before the emergence of TKI, chemotherapy, interferon therapy and bone marrow transplantation were traditional treatments for chronic particles, but the therapeutic effect was not satisfactory.

The emergence of TKI not only ushered in the era of targeted tumor therapy, but also changed the course of disease and treatment outcome of patients with chronic particles.

Chronic particles are transforming from hematological tumor diseases into chronic diseases such as hypertension and diabetes.

Therefore, in the era of TKI treatment, the goal of treatment is no longer survival, but a higher quality of life.

　　Acquired drug resistance has always been a major challenge in CML therapy.

As the main therapeutic drug at present, some patients can obtain ideal curative effect after receiving TKI treatment.

Jiang Qian reminded that it is also very important to conduct regular testing in a standardized manner. When the patient does not achieve the best response or progresses in the treatment process, it is necessary to detect the kinase mutation as soon as possible, which will help to change the treatment plan in time and reduce the treatment time. risk.

　　According to reports, there are currently no third-generation TKI drugs in China. For patients with drug resistance, poor efficacy, or advanced chronic particles, the third-generation TKI is "just needed."

Especially for the needs of patients with T315I mutation, corresponding clinical research projects have been carried out at home and abroad in recent years.

　　"The third-generation innovative TKI drugs in China are designed for the T315I mutation. I very much look forward to such original and innovative drugs that can provide more treatment opportunities for patients with drug-resistant chronic particles, especially patients with multi-drug resistance, and extend their lives. "Jiang Qian said that at present, innovative drugs have been submitted for new drug marketing applications in China, and they have been included in priority review and breakthrough treatment varieties.

It is believed that with the introduction of new drugs and the standardization of kinase mutation detection, the existing drug resistance problem is expected to be overcome, allowing more patients to benefit from it.

　　With the widespread application of TKI, the survival period of chronic granule patients has been close to that of normal people of the same age, and more and more studies have begun to pay attention to the quality of life of patients.

Jiang Qian said that although the disease has been well controlled, many young patients still hide their condition, worrying that once they are made public, they may be viewed from another perspective, which will cause great resistance to their future studies and job hunting.

　　"The ability of CML patients to return to society is very powerful, and their contribution to society is also very large. There are many outstanding CML patients who have made good contributions to their work. These people should be regarded as normal people. "Professor Jiang Qian called for CML patients not only to pay attention to disease management, but also their lives and work. At the same time, they also encourage CML patients to actively speak up, so that more people can understand the real life of CML.

I hope that all sectors of society will actively contribute their efforts and join hands to help chronic granular patients rebuild their confidence in life and return to the "big family" of society.

(over)